



## FY 2023 – Conference Call Note

Dr. Christian Hartel (CEO), Dr. Tobias Ohler (CFO) March 12, 2024

## **Disclaimer**

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.





## WACKER FY 2023 Highlights


Financials		Operations	Sustainability 💋
<b>€6.4bn</b>	SPs and volumes	Continued Headwinds	CDP Rating: Top
<b>Sales</b> (-22% yoy)		Persistently high energy, raw material	Score on
Driven primarily by lower A		costs, reduced utilization, lower ASPs	Climate Change
<b>€824m</b> <b>EBITDA</b> (2022 €2.08bn)	<b>€327m</b> Net Income (2022 €1,282m)	Strong Focus on Costs Ongoing efficiency programs support EBITDA	WACKER rated with an A rating, confirming its leading role in climate & environmental protection
<b>€84m</b>	<b>€3.00</b>	Investing in our Future	Committed to reach
Net Debt	<b>Dividend Proposal</b>	Higher CapEx to drive growth in	Net Zero emissions by
(-€409m 31.12.22)	(2022 €12 per share)	Specialties & Biotech	2045

EBITDA = Earnings before Interest, Depreciation and Amortization; ASP = Average Sales Price; CDP – Carbon Disclosure Project; CapEx = Capital expenditures



## FY 2024 Group Guidance – Committed to 2030 Targets

#### **Outlook for FY 2024**



## FY 2024 Group Guidance

- Sales of €6,000 6,500m
- EBITDA of €600 800m
- CapEx slightly below FY 2023

#### **Investing in the Future: Committed to 2030 Targets**

- Sales: > €10bn
- EBITDA Margin: >20%
- Volume/Mix CAGR: 1.5 2x Historic
- ROCE: 2x Cost of Capital
- ▶ CO<sub>2</sub>e: -50% Emissions

ROCE = Return on Capital Employed



## Strategic Investments for Future Growth Supported by Mega-Trends



## SILICONES

Burghausen & Nünchritz

- Intermediates, Hybrids
- Completion: 2024-25

Karlovy Vary

- Specialties Facility
- Completion: 2025

Zhangjiagang

- Specialties Expansion
- Completion: 2025



**POLYMERS** Calvert City:

- VAE Dispersions
- Completion: 2025



## BIOSOLUTIONS

Halle:

- mRNA Competence Center
- Completion: 2024



## POLYSILICON

Burghausen:

- Semiconductor Etching
- Completion: 2025

WACKER

## Investing in the Future: People, Markets, Molecules



#### People

- Employees are the foundation to our success
- Growth in the number of employees worldwide to 16,378, more than 1/3 outside Germany



#### **Markets**

- In the Regions for the Regions operations in all growth markets around the world
- 27 Productions sites (10 in Europe, 8 in America, 9 in Asia)
- > 22 Technical Centers globally



## **Molecules**

- Solutions for a better future enabling resource saving technologies
- Bespoke, high-performance products for individual customer applications
- Clear specialties focus



## Profit & Loss Statement €824m in EBITDA in a Continued Weak Demand Environment

## Profit & Loss (€m)

	FY 2023	FY 2022
Sales	6,402	8,209
Gross profit from sales	1,083	2,161
Gross margin	16.9%	26.3%
EBITDA	824	2,081
EBITDA margin	12.9%	25.4%
EBIT	405	1,679
EBIT margin	6.3%	20.5%
Net income	327	1,282
EPS	6.31	25.18



#### Comments


EBITDA -60% yoy

Lower ASPs, high energy & raw material costs, and reduced utilization rates



## Balance Sheet Composition Resilient Financials with €4.6bn in Equity and €1.4bn in Liquidity

## **Balance sheet (%)**




#### Characteristics 12/31/23

- Cash & Securities: High level of liquidity at €1.4bn
- Working Capital:
  -€330m lower yoy on release from inventories and receivables
- Pension Provisions: Slightly higher yoy at €835m on lower discount rates
- Shareholder Equity:
  -€450m lower yoy at €4.6bn after record dividend payment of €596m in 2023 and net income of €327m



## SILICONES FY EBITDA of €236m, Driven by Weak Demand, Low Prices and Adverse Mix Effects



## **2023 Comments**

- Weak demand across all regions, with year-end seasonality
- Low specialty volumes
- Low standards prices, stabilizing at year-end
- EBITDA burdened by demand-driven adverse mix effects, low utilization rates, trailing higher raw material costs

#### Outlook 2024

- Sales on PY level, with a mid-single-digit % EBITDA margin
- Sales in all regions at PY level
- Higher volumes in Specialties
- ASPs remain at Q4/23 exit rates
- Q1 with improved order intake, FY outlook still uncertain


1) 2022 EBITDA figures include +€72m from the revaluation of an at equity JV participation in China




## POLYMERS FY EBITDA at €253m, Defending Margins in Weak Markets



#### EBITDA (€m) / margin



CapEx (€m)



## **2023 Comments**

- Volumes below prior year level, with year-end seasonality
- ASP lower yoy following development of raws & long market
- Regions: Europe with weak market demand, Americas stable, Asia positive yoy
- EBITDA supported by positive net pricing benefits


#### Outlook 2024

- Sales lower (high-single-digit %) than PY with an EBITDA margin of around 15%
- Lower ASP at slightly higher volumes in Dispersions and stable volumes in DPP, regional dynamics unchanged to PY
- No clear signs of a pronounced demand recovery so far

DPP = Dispersible Polymer Powder




## BIOSOLUTIONS FY EBITDA at €7m, Burdened by Upfront Costs



#### EBITDA (€m) / margin



CapEx (€m)



## **2023 Comments**


- Strong growth in BioPharma sales
- EBITDA with upfront costs for the mRNA facility in Halle, integration costs from ADL acquisition
- Peak in CapEx driven by mRNA facility
- Continued weak demand and lower prices in established products

## Outlook 2024


- Sales approx. 10% higher than PY with a significantly higher EBITDA
- Sales growth driven by BioPharma and BioIngredients
- mRNA facility scheduled for completion by mid-year




## POLYSILICON FY EBITDA at €321m, Solar With Significantly Lower Prices



## EBITDA (€m) / margin



CapEx (€m)



## **2023 Comments**


- Significantly lower solar ASPs and production-related volume declines
- Resilient Semi volumes with higher prices
- Ongoing solar price differentiation
- High energy costs in Germany


#### Outlook 2024

- Sales in the range of €1.3 1.6bn, with an EBITDA in the range of €200 400m
- Volumes above PY level, with solar ASP below PY
- Mix improvement and continued cost reductions



## OTHERS Quarterly EBITDA Strongly Influenced by CO<sub>2</sub> Compensation





#### 2023 Comments


In Q4/23, CO<sub>2</sub> compensation for the FY 2023 of approx. €100m was received and recognized as income in the OTHERS segment

## **Modeling Help**

- To ensure a true and fair view on segment performance, we credit the expected annual CO<sub>2</sub> compensation quarterly to the segments, debiting Others
- Total CO<sub>2</sub> compensation in 2024 will be higher than in 2023
- Model the FY 2024 OTHERS segment EBITDA with
   €20m. Q1-Q3 negative EBITDA, Q4 positive
- Consensus for Siltronic (WAF) indicates no meaningful contribution to equity income in 2024



## Net Financial Position €936m Gross Cash Flow Supported By Release from Working Capital



WACKER

# Q1 Trading Update Sales of about €1.5bn with an EBITDA at the Level of Q4/23 at about €135m

#### SILICONES

- Sales and EBITDA sequentially higher
- Continued low ASP for Standards
- Improved order intake so far
- Preparations underway for turnaround in Q2

#### **POLYMERS**

- Sales and EBITDA sequentially higher
- Q1 benefits from seasonality
- Demand from construction with a slow start to the year

## BIOSOLUTIONS

- Profitability in Q1/24 still burdened by upfront costs for future growth
- Biopharma with sequentially lower customer project finalizations
- Growth in sales and earnings in H2/24

#### POLYSILICON

- Sales comparable, EBITDA sequentially higher
- Benefits from lower energy costs



## FY 2023 – Q&A Session





## CREATING TOMORROW'S OUR SOLUTIONS MAKE A BETTER WORLD FOR GENERATIONS



FY 2023 – Conference Call Note March 12, 2024

## Appendix Guidance FY 2024

In €m	FY 2023	Outlook 2024
Sales	6,402	€6,000 – 6,500m
EBITDA	824	€600 – 800m
EBITDA margin (%)	12.9	Substantially lower than last year
Net cash flow	166	Negative, substantially lower than last year
CapEx	710	Slightly lower than last year
Net Debt	84	Higher than last year
Net Income	327	Substantially lower than last year
Depreciation	419	Around €450m
ROCE (%)	6.9	Substantially lower than last year
Tax Rate (%)	15.4	Around 20%



## Appendix Progress Made on Achieving Ambitious Group Sustainability Targets

	2020	<b>2021</b>	2022	2023	2030 Target
Net Zero	100%	93%	87%	72%	100% reduction by 2045
Value Up					
Sustainable products	83%	89%	90%	94%	100% of products meet defined sustainability criteria
Diversity: Woman in management	17%	19%	21%	21%	33% of management positions held by woman
Regionalization: Management	27%	29%	30%	32%	50% management positions outside Germany
Footprint Down					
CO <sub>2</sub> e (Scope 1+2) emissions	100%	101%	89%	86%	50% reduction in absolute CO <sub>2</sub> e emissions
Energy consumption	100%	98%	99%	103%	15% reduction in specific energy consumption
Water withdrawal	100%	98%	102%	104%	15% reduction in specific water withdrawal
Collaboration Beyond					
CO <sub>2</sub> e (Scope 3) emissions	100%	86%	80%	62%	25% reduction in absolute $CO_2$ e emissions
Sustainable supply chain	57%	60%	72%	79%	100% of key suppliers meet defined TfS criteria
Health & Safety					
Chemical accidents with missed workdays <sup>1</sup>	3	4	10	2	0 days – reoccurring annual target
Severe process safety incidents	1	3	3	0	0 incidents – reoccurring annual target



## Appendix FY 2023 Results – Breakdown by Business

		FY 2023		FY 2022		Q4 2023			Q4 2022			
In €m / %	SALES	EBITDA	EBITDA MARGIN	SALES	EBITDA	EBITDA MARGIN	SALES	EBITDA	EBITDA MARGIN	SALES	EBITDA	EBITDA MARGIN
Chemicals	4,321	490	11.3	5,449	1,165	21.4	952	69	7.3	1,128	168	14.9
SILICONES	2,741	236	8.6	3,453	876 <sup>1</sup>	25.4	610	37	6.1	706	123 <sup>1</sup>	17.4
POLYMERS	1,580	253	16.0	1,996	289	14.5	342	32	9.3	421	45	10.6
BIOSOLUTIONS	337	7	1.9	331	17	5.0	93	12	12.6	81	5	5.9
POLYSILICON	1,599	321	20.0	2,287	826	36.1	303	21	6.8	574	197	34.3
Others	162	8	4.6	171	73	42.7	39	34	87.1	50	-14	-
Consolidation	-18	-1	-	-29	1	-	-4	0	-	-7	-1	-
WACKER Group	6,402	824	12.9	8,209	<b>2,081</b> <sup>1</sup>	25.4	1,383	135	9.8	1,827	355 <sup>1</sup>	19.4

1) includes €72m exceptional non-cash revaluation of JV in China (SILICONES)



## Appendix Strong Growth of Global PV Markets in 2024 Expected


Country	2020	2021	2022	2023	2024
Germany	5	5	8	14	14 - 18
Spain	3	4	8	8	8 - 10
Europe other	13	20	30	35	38 - 52
Europe total	21	29	45	57	60 - 80
USA	19	25	19	33	35 - 55
Japan	8	8	7	7	6 - 8
China	48	55	87	217	230 - 250
India	4	12	14	10	15 - 20
Rest of World	41	42	79	86	104 - 117
Total	140 GW	170 GW	250 GW	410 GW	450 - 530 GW


Sources: market surveys, industry announcements, WACKER estimates



## Appendix Key Raw Materials, Power and Gas











## **WACKER: Issuer, Contact and Additional Information**

#### **Issuer and Contact**

#### **INVESTOR RELATIONS CONTACTS**

Joerg Hoffmann, CFA Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com

Scott McCollister Tel. +49 89 6279 1560 | scott.mccollister@wacker.com

Wacker Chemie AG Hanns-Seidel-Platz 4, D-81737 Munich investor.relations@wacker.com

#### **Additional Information**

#### MDAX

ISIN	DE000WCH8
WKN	WCH888
Deutsche Börse	WCH
Deutsche Borse	VVCH

WCH8881 88

## **Financial Calendar**

04/25/24	Q1 2024 Results
05/08/24	Annual General Meeting, Munich
07/26/24	Q2 2024 Results
09/18+19/24	CMD Burghausen
10/29/24	Q3 2024 Results

#### **Publications**



